D. Paraïso

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group

Sophie Camilleri‐Broët, Anne‐Claire Hardy‐Bessard, A. Le Tourneau et al. · Annals of Oncology · 2003 · 109 citations

Medicine, Gynecology, Oncology +16

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

Isabelle Ray‐Coquard, Laure Favier, B. Weber et al. · British Journal of Cancer · 2013 · 105 citations · Full text

Medicine, Gynecology, Oncology +5

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial

Jean-­Marc Ferrero, B. Weber, J.-F. Geay et al. · Annals of Oncology · 2006 · 105 citations · Full text

Medicine, Gynecology, Oncology +17

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO)

Alain Lortholary, R. Largillier, B. Weber et al. · Annals of Oncology · 2011 · 92 citations · Full text

Medicine, Oncology, Pharmacology +17